GlassScriptPhysician profile
Maria B Lambert
NPI 1891288197
$6,235.48
in general payments reported to CMS, 2019-2025
29 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $962 · 2022: $1,038 · 2023: $756 · 2024: $1,974 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $24.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.25 |
| Education | $24.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,343.54 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $906.18 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $608.68 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $557.02 | 2021-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $406.93 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $372.43 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $281.73 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $277.59 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $220.11 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $189.91 | 2023-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $148.12 | 2024 | Stelara |
| Vivus LLC | $120.92 | 2021-2024 | Qsymia |
| Pfizer INC. | $76.83 | 2022-2023 | |
| Redhill Biopharma INC. | $75.97 | 2024 | Talicia |
| Merck Sharp & Dohme LLC | $75.34 | 2022-2024 | Dificid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $69.88 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $67.29 | 2023-2024 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $65.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $64.18 | 2023 | |
| Medtronic, INC. | $53.99 | 2021 | |
| Alnylam Pharmaceuticals INC. | $47.54 | 2021-2022 | |
| Qol Medical, LLC | $46.09 | 2021-2022 | |
| Evoke Pharma, INC. | $42.31 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $34.42 | 2024 | Rebyota |
| Celgene Corporation | $30.39 | 2022-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $14.84 | 2022 | |
| Ardelyx, INC. | $13.09 | 2023 | Ibsrela |
| Exact Sciences Corporation | $12.76 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.